Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules

Molecules

57 incretin-based agents and amylin analogues. Each page lists trial arms, outcome trials, registered trials, label indications and primary sources.

Data cut 12 November 2026
MoleculeMechanismRouteCompanyStageStatusArms
Danuglipron
PF-06882961, Pfizer
GLP-1 (small molecule)oralPfizerstoppedDiscontinued (2025, liver safety signal)0
Beinaglutide
Benemae
GLP-1s.c. dailyBenemaeapprovedApproved in China: T2D (2016), weight management (2023)1
Ecnoglutide
XW003
GLP-1 (biased agonist)s.c.SciwindapprovedApproved in China: T2D (January 2026) and weight management (March 2026); SLIMMER published (Lancet Diabetes Endocrinol 2025)8
Efsubaglutide alfa (supaglutide)
Yinnuo / Innogen
GLP-1s.c. weeklyYinnuo (Innogen)approvedApproved in China for T2D (January 2025); obesity phase 2b ENLIGHT positive; obesity phase 3 topline expected end-20265
Liraglutide
Saxenda / generics
GLP-1s.c. dailyNovo Nordisk / genericsapprovedApproved for obesity (2014); generics available0
Mazdutide
IBI362
GLP-1/GCGs.c.Innovent (Lilly licence)approvedApproved in China: obesity (June 2025) and T2D (September 2025); 9 mg supplementary NDA accepted (Nov 2025); GLORY-2 published (JAMA 2026)11
Orforglipron
LY3502970
GLP-1 (small molecule)oralEli LillyapprovedApproved in the US for obesity (Foundayo, 2026); T2D phase 3 positive (ACHIEVE)12
PB-119
PegBio (PEGylated exenatide)
GLP-1s.c. weeklyPegBioapprovedApproved in China for T2D (November 2025)2
PEG-loxenatide
Hansoh (Fulaimei)
GLP-1s.c. weeklyHansohapprovedApproved in China for T2D (May 2019, Fulaimei)4
Semaglutide
Wegovy / Ozempic / Rybelsus
GLP-1s.c. / oralNovo NordiskapprovedApproved: obesity, T2D, MACE reduction, CKD in T2D (Ozempic), MASH (Wegovy US 2025; Kayshild EU 2026); oral Wegovy tablets5
Tirzepatide
Zepbound / Mounjaro
GIP/GLP-1s.c.Eli LillyapprovedApproved: obesity, T2D, obstructive sleep apnoea (FDA); MACE reduction added to the Mounjaro US label (2026)7
BGM0504
BrightGene
GIP/GLP-1s.c.BrightGenefiledPhase 3 positive in China (52 weeks, up to −19.2 %); NDA accepted (June 2026)6
HDM1702
Zhongmei Huadong
GLP-1s.c.Huadong MedicinefiledSemaglutide follow-on: phase 3 equivalence to Wegovy; NDAs accepted in China (T2D Mar 2025; weight Apr 2026)1
HRS-7535
Hengrui
GLP-1 (small molecule)oralHengruifiledPhase 3 positive: OUTSTAND-1/-2 (T2D), HARBOR-1 (obesity); NDAs accepted in China for T2D and weight management (Sep 2026)9
HS-20094
Hansoh (Regeneron licence ex-China)
GIP/GLP-1s.c.HansohfiledOlatorepatide. Phase 3 LIGHTEN positive in China (−18.7 % at 48 weeks, EASD 2026); NDA accepted (June 2026); Regeneron licence ex-China3
Ribupatide (HRS9531)
KAI-9531, Hengrui / Kailera
GIP/GLP-1s.c.Hengrui / KailerafiledPhase 3 positive in China (GEMINI-1: −17.7 % TP / −19.2 % at 48 weeks); NDA accepted in China (Sep 2025); global phase 3 KaiNETIC enrolled (Kailera)16
TG103
CSPC
GLP-1s.c.CSPCfiledEfmedaglutide alfa. Phase 3 T2D non-inferior to dulaglutide; obesity NDA accepted in China (Oct 2025)2
ASC30
Ascletis (oral small molecule and injectable)
GLP-1 (small molecule)oral / s.c.Ascletisphase 3Oral phase 2 (13 weeks: placebo-adjusted −7.7 %); global phase 3 AURORA started (Aug 2026)0
AZD5004 (ECC5004)
Eccogene → AstraZeneca
GLP-1 (small molecule)oralAstraZeneca (Eccogene)phase 3Elecoglipron. Phase 2b VISTA (obesity) and SOLSTICE (T2D) positive; phase 3 started (June 2026)11
Aleniglipron
GSBR-1290, Structure Therapeutics
GLP-1 (small molecule)oralStructure Therapeuticsphase 3Two pivotal phase 3 trials (obesity; obesity with or without T2D) recruiting since Jul 2026; phase 2b ACCESS reported 20253
Amycretin
zenagamtide
GLP-1 + amylin (unimolecular)s.c. / oralNovo Nordiskphase 3Phase 3 (AMAZE) started6
Berobenatide (MET-097i)
Metsera (Pfizer)
GLP-1 (ultra-long-acting, monthly)s.c. monthlyPfizer (Metsera)phase 3Phase 3 started 2026 (monthly dosing); phase 2b VESPER reported 20250
Bofanglutide (GZR18)
Gan & Lee
GLP-1s.c. every 2 weeksGan & Leephase 3Phase 3 GRADUAL-1 positive (48 mg every 2 weeks: −18.5 % at 52 weeks); US phase 2; once-monthly GRADUAL-3 started12
CT-388
Roche / Carmot
GIP/GLP-1s.c.Rochephase 3Phase 3 (Enith1, Enith2 and a third trial) recruiting since Mar 2026; phase 2 (48 weeks) presented at EASD 20262
CagriSema
cagrilintide + semaglutide
GLP-1 + amylins.c.Novo Nordiskphase 3Phase 3 (REDEFINE); filing 20266
DR10624
Zhejiang Doer Biologics
GLP-1/GCG/FGF21s.c.Doer Biologicsphase 3Phase 3 in severe hypertriglyceridaemia; obesity/MASH in development0
EloraTZP
eloralintide + tirzepatide, Eli Lilly
GIP/GLP-1 + amylins.c.Eli Lillyphase 3Phase 2b in obesity with T2D positive (Sep 2026: up to −23.3 % vs −14.8 % with tirzepatide 15 mg); phase 3 AMPLIFY-1 and AMPLIFY-2 registered (100 weeks, start Q4 2026)4
Eloralintide
LY3841136
Amylins.c.Eli Lillyphase 3Phase 3 ENLIGHTEN programme recruiting since Dec 2025 (obesity, T2D, sleep apnoea, knee osteoarthritis, maintenance after incretin therapy); phase 2 complete3
HDM1002
Zhongmei Huadong
GLP-1 (small molecule)oralHuadong Medicinephase 3Phase 3 HDM1002-301 positive (oral; up to −12.2 % efficacy estimand at 52 weeks); pre-NDA2
HDM1005
Huadong
GIP/GLP-1s.c.Huadong Medicinephase 3Phase 3 in China (obesity; T2D; head-to-head vs mazdutide in T2D) since Oct 2025; phase 2 T2D (20 wk) at EASD 2026: HbA1c up to −2.57 %3
Lenbelintide
AZD6234, AstraZeneca
Amylins.c.AstraZenecaphase 3Phase 3 recruiting (adjunct to incretin-based therapy, 68 weeks)0
MariTide
maridebart cafraglutide
GLP-1 + GIPR antagonist (antibody)s.c. monthlyAmgenphase 3Phase 3 (MARITIME)9
Noiiglutide
SHR20004 / HS-20004, Hengrui
GLP-1s.c.Hengruiphase 3Phase 3 in T2D (China) completed; results not yet public0
Pemvidutide
ALT-801
GLP-1/GCGs.c.Altimmunephase 3Phase 3 PERFORMA in MASH recruiting since Jul 2026; phase 2 MOMENTUM (obesity) and IMPACT (MASH) complete1
Petrelintide
ZP8396
Amylins.c.Zealand / Rochephase 3Phase 3 ZUPREME programme (ZUPREME-3, -4, -5) initiated with Roche; phase 2 ZUPREME-1 published (Lancet Diabetes Endocrinol 2026), ZUPREME-2 topline in T2D (Oct 2026)6
RAY1225
Raynovent
GIP/GLP-1s.c. every 2 weeksRaynoventphase 3Phase 3 REBUILDING-2 positive (9 mg every 2 weeks: −22.2 % at 52 weeks, topline Oct 2026); licensed to Qilu9
Retatrutide
LY3437943
GIP/GLP-1/GCGs.c.Eli Lillyphase 3Phase 3 positive: TRIUMPH-1 (NEJM 2026), TRIUMPH-2/-3 and TRIUMPH-4 toplines; TRANSCEND-T2D-1 at EASD 202615
Survodutide
BI 456906
GLP-1/GCGs.c.Boehringer Ingelheim / Zealandphase 3Phase 3 positive in obesity (SYNCHRONIZE-1, NEJM 2026) and T2D (SYNCHRONIZE-2, NEJM 2026); SYNCHRONIZE-CVOT showed CV safety (non-inferior to placebo, Lancet Nov 2026)7
UBT251
United Laboratories
GIP/GLP-1/GCGs.c.United Laboratories (Novo Nordisk licence)phase 3Phase 3 in China: UNIGUIDE-1 (T2D) recruiting since Sep 2026; obesity and sleep apnoea trials registered; phase 2 (T2D) at EASD 20268
VK2735
Viking Therapeutics
GIP/GLP-1s.c. / oralViking Therapeuticsphase 3Phase 3: s.c. VANQUISH-1/-2 (since 2025); oral SUNRISE-1/-2 started Oct 2026 (obesity with and without T2D); VENTURE s.c. phase 2 published (Obesity 2026)5
Zovaglutide
ZT002, QL Biopharm
GLP-1 (ultra-long-acting, monthly)s.c.QL Biopharmphase 3Phase 3 in obesity (HORIZON-1, China, started Jan 2026)0
CT-996
Roche / Carmot
GLP-1 (small molecule)oralRochephase 2Phase 20
Cotadutide
MEDI0382, AstraZeneca
GLP-1/GCGs.c.AstraZenecaphase 2Phase 2 (MASH, CKD with T2D) completed; no phase 3 registered0
Dapiglutide
ZP7570, Zealand
GLP-1/GLP-2s.c.Zealand Pharmaphase 2Phase 20
Efinopegdutide
MK-6024
GLP-1/GCGs.c.MSD (Hanmi)phase 2Phase 2b MASH0
Efocipegtrutide
HM15211, Hanmi
GIP/GLP-1/GCGs.c.Hanmiphase 2Phase 2 in biopsy-confirmed MASH0
HEC88473
HEC
GLP-1/FGF21s.c.HECphase 2Phase 20
HRS-4729
Hengrui
GIP/GLP-1/GCGs.c.Hengruiphase 2Phase 2 master protocol in MASH recruiting since Aug 2026; phase 1 at EASD 20261
Macupatide
LY3532226, Eli Lilly
GIPs.c.Eli Lillyphase 2Phase 2 (alone and with eloralintide)0
RGT-075
Regor
GLP-1 (small molecule)oralRegorphase 2Phase 2b (36 weeks) presented at EASD 20261
ASC35 / ASC36
Ascletis
GIP/GLP-1 + amylin (monthly co-formulation)s.c. monthlyAscletisphase 1Phase 1 single and multiple ascending dose study recruiting since Aug 2026; preclinical data at EASD 20260
Albiglutide
Tanzeum (withdrawn)
GLP-1s.c.GSK—Withdrawn from market (2018) despite positive CVOT0
DD1013
Huadong
GLP-1 + GIP + amylin (triple)s.c.Huadong MedicinepreclinicalPreclinical (EASD 2026)0
Dulaglutide
Trulicity
GLP-1s.c.Eli Lilly—Approved (T2D); not developed for obesity0
Efpeglenatide
Hanmi / Sanofi
GLP-1s.c.Hanmi—Positive CVOT (AMPLITUDE-O); development paused0
Exenatide
Bydureon / Byetta
GLP-1s.c.AstraZeneca—Approved (T2D)0
Lixisenatide
Lyxumia / Adlyxin
GLP-1s.c.Sanofi—Approved (T2D); neutral CVOT0